Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
|ClinicalTrials.gov Identifier: NCT00001503|
Recruitment Status : Enrolling by invitation
First Posted : November 4, 1999
Last Update Posted : November 8, 2017
|Condition or disease|
|Melanoma Ovarian Cancer Prostate Cancer Breast Cancer Lymphoma|
- Patients enrolled on CCR clinical protocols may require long term follow-up to assess outcome (e.g., survival) or the effects of prior therapy.
- Keeping the primary treatment protocols open after accrual is complete in order to follow patients for long term outcome is an administrative burden on investigators and the IRB.
-To provide follow-up for patients who are long term survivors previously enrolled Center for Cancer Research (CCR) trial but who may not currently be enrolled on a research protocol.
-Patients who were previously enrolled on a CCR protocol and who are not eligible for an active NCI intramural primary research protocol.
- The medical procedures/tests will be based on the patient's diagnosis, treatment and supporting clinical information. This is a follow-up study in which only standard tests and procedures are to be performed.
- Clinical information that is relevant to the patients prior protocols will be collected for research purposes.
- Procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.
|Study Type :||Observational|
|Actual Enrollment :||990 participants|
|Official Title:||Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols|
|Study Start Date :||May 2, 1996|
- To provide follow-up for patients who are long term survivors previously enrolled Center for Cancer Research (CCR) trial but who may not currently be enrolled on a research protocol [ Time Frame: 30 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001503
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Caryn Steakley, R.N.||National Cancer Institute (NCI)|